A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
Semaglutide medications like Ozempic and Wegovy suppress appetite and accelerate weight loss, but experts warn that inadequate protein intake may increase the risk of muscle loss. Here’s why protein has become a major focus for GLP-1 users and how clinicians recommend protecting lean mass during treatment.